论文部分内容阅读
目的：探讨α－颗粒膜蛋白（ＧＭＰ－１４０）与Ⅱ型糖尿病的关系，为临床诊断和治疗提供依据。方法：用放射免疫分析对１０４例（有微血管病变５５例，无微血管病变４９例）非胰岛素依赖性糖尿病（ＮＩＤＤＭ）患者和３８例健康人血小板ＧＭＰ－１４０、血浆ＧＭＰ－１４０进行测定及血小板直接计数。结果：ＮＩＤＤＭ患者血小板ＧＭＰ－１４０、血浆ＧＭＰ－１４０水平显著高于对照组（Ｐ＜０．００１）；有微血管病变ＮＩＤＤＭ与无微血管病变ＮＩＤＤＭ患者血小板ＧＭＰ－１４０、血浆ＧＭＰ－１４０水平比较差异有高度显著性（Ｐ＜０．００１）。有微血管病变和无微血管病变患者的血小板ＧＭＰ－１４０与血浆ＧＭＰ－１４０均呈显著正相关（ｒ１＝０．６９，ｒ２＝０．７５）；ＮＩＤＤＭ患者血小板计数与对照组比较差异无显著性（Ｐ＞０．０５）；ＮＩＤＤＭ患者在控制血糖（＜７．８ｍｍｏｌ／Ｌ）前提下服用阿斯匹林６个月后，复查眼底及ＧＭＰ－１４０，结果与治疗前无明显差异。结论：ＮＩＤＤＭ患者微血管病变与血小板功能及ＧＭＰ－１４０水平的变化有着十分密切的关系。
Objective: To investigate the relationship between α-granule membrane protein (GMP-140) and type Ⅱ diabetes mellitus (T2DM) and provide the basis for clinical diagnosis and treatment. Methods: Radioimmunoassay was used to detect platelet GMP-140 and plasma GMP-140 in 104 patients (55 with microangiopathy and 49 without microvascular disease) and 38 healthy controls without NIDDM count. Results: The levels of platelet GMP-140 and plasma GMP-140 in patients with NIDDM were significantly higher than those in controls (P <0.001). There was significant difference in platelet GMP-140 and plasma GMP-140 levels between NIDDM patients without microangiopathy and without NIDDM Highly significant (P <0.001). There was a significant positive correlation between platelet GMP-140 and plasma GMP-140 (r1 = 0.69, r2 = 0.75) in patients with microangiopathy and without microangiopathy. There was no significant difference in platelet count between patients with NIDDM and control P> 0.05). After aspirin administration for 6 months in patients with NIDDM under control of blood glucose (<7.8 mmol / L), the fundus and GMP-140 were examined. There was no significant difference between before and after treatment. Conclusion: The microvascular lesions in patients with NIDDM are closely related to the changes of platelet function and GMP-140 levels.